Opthea Ltd. plans to raise AU$80 million (US$51.2 million) via a AU$10 million private placement and a AU$70 million entitlement offer to continue its pivotal phase III trials in wet age-related macular degeneration (wet AMD) for lead candidate OPT-302.
With approval, aflibercept 8 mg becomes the first and only treatment approved in wAMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.
Last week, Celltrion filed an IPR petition, PTAB IPR2023-00462, seeking cancellation of claims 1-18 of U.S. Patent No. 10,464,992 ("the '992 patent"), assigned to Regeneron Pharmaceuticals, Inc.
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has granted pediatric exclusivity for EYLEA Injection. This extends the period of U.S. market exclusivity for EYLEA
LEVERKUSEN (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has accepted for Priority Review the supplemental Biologics License Application for EYLEA Injection to treat Retinopathy